# A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers

> **NCT00931073** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 24 (estimated)

## Conditions studied

- Alzheimer's Disease
- Huntington's Disease

## Interventions

- **DRUG:** Dimebon alone
- **DRUG:** Dimebon + Ketoconazole
- **DRUG:** Dimebon + Omeprazole

## Key facts

- **NCT ID:** NCT00931073
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2009-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00931073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00931073, "A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00931073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*